Philips launches Minicare I-20 troponin blood test for rapid diagnosis of heart attack at the point of care

  • Latest innovation from Philips in point-of-care testing has CE marked for compliance with the European in vitro diagnostic medical devices directive
  • Minicare I-20 handheld device for use in emergency department provides results in 10 minutes from a droplet of blood instead of 60 minute wait
  • Supports ruling out heart attack (myocardial infarction) in three hours

May 25, 2016

Eindhoven, the Netherlands – Chest pain patients presenting at the emergency department are set to benefit from a major development by Royal Philips (NYSE: PHG, AEX: PHIA). The company today announced that it has CE marked its cardiac troponin I (cTnI) blood test on the Minicare I-20 handheld device. Minicare cTnI delivers its lab comparable test results in less than 10 minutes near the patient, reducing the time for the physician to decide on treatment.


Only a single droplet of blood needs to be taken from the patient. The result is delivered while the patient is being assessed and a medical history taken, reducing the time for the physician to decide on treatment. By doing so, this simplifies the patient-doctor interaction, helping physicians provide the best possible care for their patients.


Current guidelines for the diagnosis of myocardial infarction require blood test results of the biomarker cardiac troponin for the 90% of patients who present at the emergency department (ED) with chest pain but are not diagnosed by an ECG.


“Blood samples are usually analysed in the hospital laboratory, which can easily take more than an hour to get the result back to the ED physician. Point of care testing can significantly help to reduce the turnaround time,” said Dr. Paul Collinson, consultant chemical pathologist at St George’s University Hospitals NHS Foundation Trust.


For high-risk cardiac patients (such as those with Acute Coronary Syndrome), fast triage and rapid initiation of treatment are critical in order to improve patient outcomes and to save lives. Only 10% of chest pain patients can be diagnosed by an electrocardiogram (ECG), the rest need to rely on additional cardiac marker testing for the diagnosis of myocardial infarction. Physicians often have to wait up to six hours before it can be decided if they can safely discharged the patients or if they need to admit them into hospital for further tests.


It is essential to diagnose myocardial infarction as soon as possible. The use of Minicare cTnI supports a reduction of the diagnostic protocol by up to three hours.


“Minicare I-20 is designed to help care providers to reduce time to treatment and reduce time to discharge of patients, thereby helping to decrease crowding in the emergency department and leading to better use of hospital resources,” said Marcel van Kasteel, CEO of Handheld Diagnostics at Philips.


Lab2Go Study confirmation


The Minicare I-20 was tested in real life acute care settings within the European project Lab2Go, a consortium of European hospitals. The study showed the potential of the Philips Minicare cTnI to accurately measure cTnI values, near the patient in the emergency department, with a turn-around-time of less than 10 minutes.


Minicare I-20 is simple and easy to use by non-laboratory staff. The intuitive interface and incorporated fail-safes guide the user through the process steps. A droplet of blood from a finger prick or venous whole blood tube can be applied directly on the cartridge. Connectivity allows for direct transfer of the data to the laboratory or hospital information systems to update the patient files. The robustness and accuracy that is needed for confident decision making is provided by integrated calibration and fail-safe guarantees.




The clinical and analytical performance of Philips Minicare cTnI was validated during multicenter clinical studies. Minicare cTnI point of care assay showed excellent clinical performance for the diagnosis of myocardial infarction comparable to central laboratory assays. Minicare cTnI can be used as an aid in the diagnosis of an acute myocardial infarction (AMI) in a diagnostic protocol, including a cTn test, when the patient presents at the emergency department; and 2-4 hours later (0/3h diagnostic protocol) in appropriate patients. This follows the 2015 European Society of Cardiology (ESC) guidelines for the management of NSTE-ACS patients.

Note to Editor

The Philips Minicare I-20 analyser and Minicare cTnI test cartridges are sold in selected countries in Europe, including Austria, Belgium, Denmark, Germany, Netherlands, Norway, Sweden, UK and Switzerland. Please contact your local Philips representative for availability in your country.

For further information, please contact:

Steve Klink

Philips Group Communications

Tel.: +31 6 10888824



Hans Driessen

Philips Handheld Diagnostics

Tel: +31 6 1061 0417



Jonathan Falcone

Philips UKI, External Communications Manager

Tel: 07711 462 865


About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring health informatics, as well as in consumer  health and home care. Philips’ wholly owned subsidiary Philips Lighting is the global leader in lighting products, systems and services. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 105,000 employees with sales and services in more than 100 countries. News about Philips can be found at